News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Deals and strategy
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides an overview of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, volatility, market capitalization, and details on recent and upcoming earnings reports, revenue, and net income. The article …
LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 9:00 a.m. Eastern Time. A live webcast …
Kiniksa Pharmaceuticals director Richard S. Levy received an award of 403 Restricted Share Units (RSUs) on August 1, 2026. These RSUs vested immediately upon grant and were subsequently converted into 403 Class A Ordinary Shares. Following this transaction, Levy's direct holdings in the company …
Kiniksa Pharmaceuticals International, plc KNSA used its second-quarter 2026 earnings call to emphasize accelerating ARCALYST adoption and a higher full-year sales outlook. Management also moved KPL-387 into pivotal testing, adding a second major execution priority. The quarter's financial results supplied context rather than the …
A director at Kiniksa Pharmaceuticals International, plc (KNSA), Cole G Bradley, reported two share dispositions on July 29, 2026. He sold 3,673 Class A Ordinary Shares for $81.43 each and gifted 4,500 shares to a donor advised fund. The transactions were not executed under …
Madrigal Pharmaceuticals MDGL reported second-quarter 2026 loss of $1.99 per share, narrower than the Zacks Consensus Estimate of a loss of $2.55. In the same quarter last year, the company had incurred a loss of $1.50 per share. In the second quarter, MDGL generated …
OMERS ADMINISTRATION Corp reported a new investment in Kiniksa Pharmaceuticals International, plc, acquiring 13,100 shares valued at $631,000 during the first quarter. This increased institutional interest comes alongside several positive analyst price target revisions for KNSA, with an average target of $87.38 and primarily …
Kiniksa Pharmaceuticals International, plc (KNSA) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company. The upward trend …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Kiniksa Pharmaceuticals International (KNSA) just raised its 2026 net product revenue guidance to a …
Kiniksa Pharmaceuticals International, plc recently reported its second-quarter 2026 results, with revenue rising to US$243.6 million and net income to US$25.43 million, and it raised full-year 2026 net product revenue guidance to a range of US$980 million to US$995 million from US$930 million to …
A holder of Kiniksa Pharmaceuticals (KNSA) Class A ordinary shares plans to sell 3,673 shares under Rule 144 through Charles Schwab & Co., Inc. The aggregate market value of these shares is $299,092.00, and they are listed on NASDAQ. The sale is related to …
Kiniksa Pharmaceuticals International, plc has filed a Rule 144 notice for the potential sale of Class A Ordinary Shares. The filing indicates 45,049 shares linked to an employee stock option exercise from July 29, 2026, and 22,013 shares related to equity compensation (PSU/RSU) from …
Arrowstreet Capital Limited Partnership reduced its stake in Kiniksa Pharmaceuticals International (NASDAQ:KNSA) by 16.4% in the first quarter, selling 175,550 shares and retaining 892,666 shares valued at $42,982,000. Other institutional investors also adjusted their holdings, while company insiders, including a CEO and an insider, …
(RTTNews) - Today's top biotech gainers include Trinity Biotech, which recently completed reverse split; OPKO Health, driven by its second-quarter financial results and continued pipeline progress; Kiniksa Pharma, after raising its revenue outlook on strong commercial momentum; and MapLight Therapeutics, which staged a sharp …
Kiniksa Pharmaceuticals International plc (KNSA) stock surged by 22.7% after Wedbush, Wells Fargo, and Goldman Sachs raised their price targets, citing strong momentum for its drug Arcalyst and a large market opportunity. The increased targets range from $72 to $75, though analysts also warned …
Search by ticker symbol or company name and select a result to open its chart.